The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 Diabetes
Open accessAbstract
OBJECTIVES: This study aimed to identify clinical features associated with premature mortality in a large contemporary cohort of adults with type 1 diabetes. RESEARCH DESIGN AND METHODS: The Finnish Diabetic Nephropathy (FinnDiane) study is a national multicenter prospective follow-up study of 4,201 adults with type 1 diabetes from 21 university and central hospitals, 33 district hospitals, and 26 primary health care centers across Finland. RESULTS: During a median 7 years of follow-up, there were 291 deaths (7%), 3.6-fold (95% CI 3.2–4.0) more than that observed in the age- and sex-matched general population. Excess mortality was only observed in individuals with chronic kidney disease. Individuals with normoalbuminuria showed no excess mortality beyond the general population (standardized mortality ratio [SMR] 0.8, 95% CI 0.5–1.1), independent of the duration of diabetes. The presence of microalbuminuria, macroalbuminuria, and end-stage kidney disease was associated with 2.8, 9.2, and 18.3 times higher SMR, respectively. The increase in mortality across each stage of albuminuria was equivalent to the risk conferred by preexisting macrovascular disease. In addition, the glomerular filtration rate was independently associated with mortality, such that individuals with impaired kidney function, as well as those demonstrating hyperfiltration, had an increased risk of death. CONCLUSIONS: An independent graded association was observed between the presence and severity of kidney disease and mortality in a large contemporary cohort of individuals with type 1 diabetes. These findings highlight the clinical and public health importance of chronic kidney disease and its prevention in the management of type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Diabetic nephropathy, whether manifesting as microalbuminuria, macroalbuminuria, or a reduced glomerular filtration rate progressively augments the overall risk of macrovascular complications.118”
From Type 1 diabetes (2018) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, UACR is a continuous measurement, and differences within the normal and abnormal ranges are associated with kidney and cardiovascular outcomes (6,10,11).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, UACR is a continuous measurement, and differences within the normal and abnormal ranges are associated with kidney and cardiovascular outcomes (6,11,12).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [12]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885 · cited 3×
“9* Any retinopathy 76 (29)† 1,313 (50) 420 (93)† 290 (99)† Retinopathy requiring laser therapy 27 (10)† 683 (25) 360 (78)† 288 (97)† Current smoker 98 (37)† 614 (24) 95 (22) 49 (16)† Established macrovascular disease 31 (11)† 123 (5) 116 (25)† 138 (47)† Macroalbuminuria 2 (3)† 210 (8) 338 (73)† N/A Microalbuminuria 2…”
MethodIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Goodpasture syndrome during the course of a Schönlein-Henoch purpura
Carreras, L., Poveda, R., Bas, J., Mestre, M., Rama, I., & Carrera, M. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32799 · Cited by 1,474
Albuminuria reflects widespread vascular damage: The Steno hypothesis
Deckert, T., Feldt-Rasmussen, B., Borch-Johnsen, K., Jensen, T., & Kofoed-Enevoldsen, A. (1989) · Diabetologia · doi:10.1007/bf00285287 · Cited by 1,400
Doqi, K. (2002) · American Journal of Kidney Diseases · Cited by 1,285
Global guideline for type 2 diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.001 · Cited by 1,064
Conditioning Diagnostics: Collinearity and Weak Data in Regression
Goldstein, R. (1993) · Technometrics · doi:10.1080/00401706.1993.10484997 · Cited by 911
(2004) · doi:10.1177/0049124103262065 · Cited by 906
Can clinical factors estimate insulin resistance in type 1 diabetes?
Williams, K. V., Erbey, J. R., Becker, D., Arslanian, S., & Orchard, T. J. (2000) · Diabetes · doi:10.2337/diabetes.49.4.626 · Cited by 640
Conditioning Diagnostics: Collinearity and Weak Data in Regression.
Pettit, L., & Belsley, D. A. (1992) · Applied Statistics · doi:10.2307/2348093 · Cited by 570
Orchard, T. J., Olson, J. C., Erbey, J. R., Williams, K., Forrest, K. Y.-Z., Smithline Kinder, L., Ellis, D., & Becker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1374 · Cited by 492 · cited 4×
“2)* Macroalbuminuria 578 40 (45)* 3 (3)* 18 (20)* 28 (31)* 89 (15.”
BackgroundMethodInfluentialPredictors of mortality in insulin dependent diabetes: 10 year observational follow up study
Rossing, P., Hougaard, P., Borch-Johnsen, K., & Parving, H.-H. (1996) · BMJ · doi:10.1136/bmj.313.7060.779 · Cited by 428 · cited 3×
“2)* Macroalbuminuria 578 40 (45)* 3 (3)* 18 (20)* 28 (31)* 89 (15.”
Metabolic Syndrome in Type 1 Diabetes
Thorn, L. M., Forsblom, C., Fagerudd, J., Thomas, M. C., Pettersson-Fernholm, K., Saraheimo, M., Wadén, J., Rönnback, M., Rosengård-Bärlund, M., Björkesten, C.-G. A., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.8.2019 · Cited by 423 · cited 5×
“Insulin resistance has also been associated with cardiovascular disease in individuals with type 1 diabetes (20), although this relationship is confounded by the strong association between the insulin sensitivity and chronic kidney disease in type 1 diabetes (7).”
BackgroundMethodInfluentialSelf-citationDecreasing Incidence of Severe Diabetic Microangiopathy in Type 1 Diabetes
Hovind, P., Tarnow, L., Rossing, K., Rossing, P., Eising, S., Larsen, N., Binder, C., & Parving, H.-H. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1258 · Cited by 376 · cited 2×
“6* Hypertension 1,344 (59) 444 (88) 557 (96) 288 (97) Systolic blood pressure (mmHg) 129 15 136 16* 145 20* 153 25* Diastolic blood pressure (mmHg) 78 9 80 10* 83 10* 86 13* Medication use ACE inhibition 204 (9) 271 (54)† 425 (75)† 61 (21) Angiotensin receptor blocker 44 (2) 42 (8)† 75 (13)† 31 (5)† Calcium channel bl…”
BackgroundMessent, J. W. C., Elliott, T. G., Hill, R. D., Jarrett, R. J., Keen, H., & Viberti, G. (1992) · Kidney International · doi:10.1038/ki.1992.128 · Cited by 328 · cited 5×
“3) Microalbuminuria 504 15 (56)* 1 (4) 3 (11)* 7 (30)* 26 (5.”
InfluentialExplained Variation for Survival Models
Royston, P. (2006) · The Stata Journal: Promoting communications on statistics and Stata · doi:10.1177/1536867x0600600105 · Cited by 303 · cited 5×
“Cox model performance was judged by the explained variation using 5,000 bootstrap repetitions of the whole dataset, adjusting for covariates (18).”
MethodInfluentialBARRETT-CONNOR, E., & WINGARD, D. L. (1983) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113654 · Cited by 289 · cited 3×
“7)† ESKD 293 78 (58)† 7 (5)† 24 (18)† 26 (19)† 135 (46.”
Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients
Saraheimo, M., Teppo, A.-M., Forsblom, C., Fagerudd, J., & Groop, P.-H. (2003) · Diabetologia · doi:10.1007/s00125-003-1194-5 · Cited by 255 · cited 7×
“We also acknowledge all the physicians and nurses at each participating center for their invaluable role in patient recruitment and collection of samples and data (previously presented in detail) (8).”
BackgroundMethodInfluentialSelf-citationMultivariable Modeling with Cubic Regression Splines: A Principled Approach
Royston, P., & Sauerbrei, W. (2007) · The Stata Journal: Promoting communications on statistics and Stata · doi:10.1177/1536867x0700700103 · Cited by 226 · cited 1×
“Covariate functional form (including assessment of nonlinear effects) was judged by residual-by-time analysis, fractional polynomials (13), and (cubic) regression splines (14).”
MethodEndothelial Dysfunction Precedes Development of Microalbuminuria in IDDM
Stehouwer, C. D. A., Andreas Fischer, H. R., Van Kuijk, A. W. R., Polak, B. C. P., & Donker, A. J. M. (1995) · Diabetes · doi:10.2337/diab.44.5.561 · Cited by 222 · cited 3×
“2)* Macroalbuminuria 578 40 (45)* 3 (3)* 18 (20)* 28 (31)* 89 (15.”
BackgroundPrevalence of asymptomatic myocardial ischaemia in diabetic subjects.
Koistinen, M. J. (1990) · BMJ · doi:10.1136/bmj.301.6743.92 · Cited by 221 · cited 3×
“6* Hypertension 176 (65) 1,888 (70) 444 (96)† 288 (97)† Systolic blood pressure (mmHg) 128 14 132 16 145 20* 153 25* Diastolic blood pressure (mmHg) 78 9 79 9 81 10* 86 13* Medication use ACE inhibition 30 (11)† 611 (23) 294 (64)† 61 (21) Angiotensin receptor blocker 3 (1)† 118 (4) 55 (12)† 31 (5)† Calcium channel blo…”
BackgroundA strategy for modelling the effect of a continuous covariate in medicine and epidemiology
Royston, P. (2000) · Statistics in Medicine · doi:10.1002/1097-0258(20000730)19:14<1831::aid-sim502>3.0.co;2-1 · Cited by 219 · cited 3×
“6* Hypertension 1,344 (59) 444 (88) 557 (96) 288 (97) Systolic blood pressure (mmHg) 129 15 136 16* 145 20* 153 25* Diastolic blood pressure (mmHg) 78 9 80 10* 83 10* 86 13* Medication use ACE inhibition 204 (9) 271 (54)† 425 (75)† 61 (21) Angiotensin receptor blocker 44 (2) 42 (8)† 75 (13)† 31 (5)† Calcium channel bl…”
MethodChico, A., Pérez, A., Córdoba, A., Arcelús, R., Carreras, G., de Leiva, A., González-Sastre, F., & Blanco-Vaca, F. (1998) · Diabetologia · doi:10.1007/s001250050969 · Cited by 201 · cited 3×
“6* Hypertension 1,344 (59) 444 (88) 557 (96) 288 (97) Systolic blood pressure (mmHg) 129 15 136 16* 145 20* 153 25* Diastolic blood pressure (mmHg) 78 9 80 10* 83 10* 86 13* Medication use ACE inhibition 204 (9) 271 (54)† 425 (75)† 61 (21) Angiotensin receptor blocker 44 (2) 42 (8)† 75 (13)† 31 (5)† Calcium channel bl…”
BackgroundAstrup, A. S., Tarnow, L., Rossing, P., Hansen, B. V., Hilsted, J., & Parving, H.-H. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1242 · Cited by 182 · cited 2×
“1)* Estimated GFR 120 272 5 (42) 1 (8) 1 (8) 5 (42) 12 (4.”
BackgroundPrediction of Clinical Diabetic Nephropathy in IDDM Patients: Alternatives to Microalbuminuria?
Mogensen, C. E. (1990) · Diabetes · doi:10.2337/diab.39.7.761 · Cited by 180
Predictive value of microalbuminuria in patients with insulin-dependent diabetes of long duration.
Forsblom, C. M., Groop, P. H., Ekstrand, A., & Groop, L. C. (1992) · BMJ · doi:10.1136/bmj.305.6861.1051 · Cited by 162 · cited 6×
“6* Hypertension 176 (65) 1,888 (70) 444 (96)† 288 (97)† Systolic blood pressure (mmHg) 128 14 132 16 145 20* 153 25* Diastolic blood pressure (mmHg) 78 9 79 9 81 10* 86 13* Medication use ACE inhibition 30 (11)† 611 (23) 294 (64)† 61 (21) Angiotensin receptor blocker 3 (1)† 118 (4) 55 (12)† 31 (5)† Calcium channel blo…”
InfluentialSelf-citationThe Role of AGEs and AGE Inhibitors in Diabetic Cardiovascular Disease
Thomas, M., Baynes, J., Thorpe, S., & Cooper, M. (2005) · Current Drug Targets · doi:10.2174/1389450054021873 · Cited by 159 · cited 3×
“sion (24), oxidative stress, insulin resistance (7), inflammation (8), dyslipidemia (25), elevated plasma homocysteine (26), the accumulation of advanced glycation end products (27), anemia (28), left ventricular hypertrophy (29), arterial calcification (30), and endothelial dysfunction (31).”
BackgroundSelf-citationEstimating treatment effects in randomized clinical trials in the presence of non-compliance
Nagelkerke, N., Fidler, V., Bernsen, R., & Borgdorff, M. (2000) · Statistics in Medicine · doi:10.1002/1097-0258(20000730)19:14<1849::aid-sim506>3.0.co;2-1 · Cited by 159
Amin, R., Turner, C., Aken, S. V., Bahu, T. K., Watts, A., Lindsell, D. R., Dalton, R. N., & Dunger, D. B. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00590.x · Cited by 150 · cited 1×
“In so far as hyperfiltration precedes progressive kidney disease (34,35), this association is not surprising, and probably reflects early pathological changes both in the kidney and in other parts of the vasculature.”
BackgroundIbrahim, H. N., Mondress, M., Tello, A., Fan, Y., Koopmeiners, J. S., & Thomas, W. T. B. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004080692 · Cited by 127 · cited 2×
“6* Hypertension 1,344 (59) 444 (88) 557 (96) 288 (97) Systolic blood pressure (mmHg) 129 15 136 16* 145 20* 153 25* Diastolic blood pressure (mmHg) 78 9 80 10* 83 10* 86 13* Medication use ACE inhibition 204 (9) 271 (54)† 425 (75)† 61 (21) Angiotensin receptor blocker 44 (2) 42 (8)† 75 (13)† 31 (5)† Calcium channel bl…”
BackgroundBruno, G., Merletti, F., Bargero, G., Novelli, G., Melis, D., Soddu, A., Perotto, M., Pagano, G., & Cavallo‐Perin, P. (2007) · Diabetologia · doi:10.1007/s00125-007-0616-1 · Cited by 117 · cited 4×
“6* Hypertension 1,344 (59) 444 (88) 557 (96) 288 (97) Systolic blood pressure (mmHg) 129 15 136 16* 145 20* 153 25* Diastolic blood pressure (mmHg) 78 9 80 10* 83 10* 86 13* Medication use ACE inhibition 204 (9) 271 (54)† 425 (75)† 61 (21) Angiotensin receptor blocker 44 (2) 42 (8)† 75 (13)† 31 (5)† Calcium channel bl…”
ResultInfluentialLong-term mortality in nationwide cohorts of childhood-onset type 1 diabetes in Japan and Finland
Asao, K., Sarti, C., Forsen, T., Hyttinen, V., Nishimura, R., Matsushima, M., Reunanen, A., Tuomilehto, J., Tajima, N., & for the Diabetes Epidemiology Research International (DERI) Mortality Study Group (2003) · Diabetes Care · doi:10.2337/diacare.26.7.2037 · Cited by 102
Improved prognosis in type 1 diabetic patients with nephropathy: A prospective follow-up study
Astrup, A. S., Tarnow, L., Rossing, P. R., Pietraszek, L., Hansen, P. R., & Parving, H. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00521.x · Cited by 94 · cited 1×
“Although it is possible to argue that improvements in diabetic management have not led to changes in the relative risk of mortality in individuals with chronic kidney disease, there is little doubt that the absolute risk reduction has been considerable over this time period, via the prevention of chronic kidney diseas…”
BackgroundInfluence of Albuminuria on Cardiovascular Risk in Patients With Stable Coronary Artery Disease
Solomon, S. D., Lin, J., Solomon, C. G., Jablonski, K. A., Rice, M. M., Steffes, M. W., DOMANSKI, M. J., Hsia, J. A., Gersh, B. J., Arnold, J. M. O., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.723270 · Cited by 89 · cited 2×
“9* Any retinopathy 76 (29)† 1,313 (50) 420 (93)† 290 (99)† Retinopathy requiring laser therapy 27 (10)† 683 (25) 360 (78)† 288 (97)† Current smoker 98 (37)† 614 (24) 95 (22) 49 (16)† Established macrovascular disease 31 (11)† 123 (5) 116 (25)† 138 (47)† Macroalbuminuria 2 (3)† 210 (8) 338 (73)† N/A Microalbuminuria 2…”
ResultShankar, A., Klein, R., Klein, R., & Moss, S. E. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm096 · Cited by 88 · cited 3×
“6* Hypertension 1,344 (59) 444 (88) 557 (96) 288 (97) Systolic blood pressure (mmHg) 129 15 136 16* 145 20* 153 25* Diastolic blood pressure (mmHg) 78 9 80 10* 83 10* 86 13* Medication use ACE inhibition 204 (9) 271 (54)† 425 (75)† 61 (21) Angiotensin receptor blocker 44 (2) 42 (8)† 75 (13)† 31 (5)† Calcium channel bl…”
BackgroundAnemia in Patients with Type 1 Diabetes
Thomas, M. C., MacIsaac, R. J., Tsalamandris, C., Molyneaux, L. M., Goubina, I., Fulcher, G., Yue, D. K., & Jerums, G. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0678 · Cited by 81 · cited 1×
“sion (24), oxidative stress, insulin resistance (7), inflammation (8), dyslipidemia (25), elevated plasma homocysteine (26), the accumulation of advanced glycation end products (27), anemia (28), left ventricular hypertrophy (29), arterial calcification (30), and endothelial dysfunction (31).”
BackgroundSelf-citationRelationship between lipid profiles and kidney function in patients with type 1 diabetes
Tolonen, N., Forsblom, C. M., Thorn, L. M., Wadén, J., Rosengård‐Bärlund, M., Saraheimo, M., Heikkilä, O., Pettersson-Fernholm, K., Taskinen, M., Groop, P., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0858-y · Cited by 73 · cited 2×
“sion (24), oxidative stress, insulin resistance (7), inflammation (8), dyslipidemia (25), elevated plasma homocysteine (26), the accumulation of advanced glycation end products (27), anemia (28), left ventricular hypertrophy (29), arterial calcification (30), and endothelial dysfunction (31).”
BackgroundSelf-citationMultiple Lipoprotein Abnormalities in Type I Diabetic Patients With Renal Disease
Groop, P., Elliott, T., Friedman, R., Viberti, G., Ekstrand, A., Franssila, A.-K., & Taskinen, M. (1996) · Diabetes · doi:10.2337/diab.45.7.974 · Cited by 72 · cited 3×
“6* Hypertension 176 (65) 1,888 (70) 444 (96)† 288 (97)† Systolic blood pressure (mmHg) 128 14 132 16 145 20* 153 25* Diastolic blood pressure (mmHg) 78 9 79 9 81 10* 86 13* Medication use ACE inhibition 30 (11)† 611 (23) 294 (64)† 61 (21) Angiotensin receptor blocker 3 (1)† 118 (4) 55 (12)† 31 (5)† Calcium channel blo…”
BackgroundSelf-citationLong-term predictors of coronary artery disease and mortality in type 1 diabetes
Weis, U. (2001) · QJM · doi:10.1093/qjmed/94.11.623 · Cited by 66 · cited 2×
“Although hyperglycemia has been implicated in the development of microvascular complications in type 1 diabetes, an association between glycemic control and mortality has only been observed in some (36), but not all studies (20,37).”
BackgroundLong-Term Mortality and Incidence of Renal Dialysis and Transplantation in Type 1 Diabetes Mellitus
Stadler, M., Auinger, M., Anderwald, C. H., Kästenbauer, T., Kramar, R., Feinböck, C., Irsigler, K., Kronenberg, F., & Prager, R. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1058 · Cited by 55 · cited 1×
“A significant association between A1C and mortality was also present in individuals with a kidney transplant, consistent with previous reports (38).”
ResultBlood Pressure Lowering for the Prevention and Treatment of Diabetic Kidney Disease
Thomas, M. C., & Atkins, R. C. (2006) · Drugs · doi:10.2165/00003495-200666170-00005 · Cited by 53
Self-citationUrinary oxidative stress markers in young patients with type 1 diabetes
Hata, I., KAJI, M., HIRANO, S., SHIGEMATSU, Y., TSUKAHARA, H., & MAYUMI, M. (2006) · Pediatrics International · doi:10.1111/j.1442-200x.2006.02156.x · Cited by 39 · cited 1×
“Finally, it is possible that our results were biased by residual confounding by factors not measured in the study but potentially related to cardiovascular disease/mortality in type 1 diabetes, including silent cardiovascular disease, lipoprotein subclasses (40), oxidative stress (41), and endothelial (31) and autonom…”
BackgroundHosmer and Lemeshow type Goodness-of-Fit Statistics for the Cox Proportional Hazards Model
May, S. J., & Hosmer, D. W. (2003) · Handbook of statistics · doi:10.1016/s0169-7161(03)23021-2 · Cited by 37 · cited 1×
“Overall, Cox model fit was assessed by 1) approximation of cumulative Cox-Snell residuals to (-log) Kaplan-Meier estimates, residual plots, and specific testing of the proportional hazards assumption (15) and 2) Harrell’s C statistic (16) and “added-variable” goodness-of-fit tests (17).”
Method(2003) · Handbook of statistics · doi:10.1016/s0169-7161(00)x0001-6 · Cited by 35
Sampson, M., Chambers, J. B., Sprigings, D. C., & Drury, P. (1990) · Diabetic Medicine · doi:10.1111/j.1464-5491.1990.tb01346.x · Cited by 27 · cited 3×
“sion (24), oxidative stress, insulin resistance (7), inflammation (8), dyslipidemia (25), elevated plasma homocysteine (26), the accumulation of advanced glycation end products (27), anemia (28), left ventricular hypertrophy (29), arterial calcification (30), and endothelial dysfunction (31).”
BackgroundMaahs, D. M., Snell‐Bergeon, J. K., Kinney, G. L., Wadwa, R. P., Garg, S. K., Ogden, L. G., & Rewers, M. (2007) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2006.04.004 · Cited by 26 · cited 3×
“sion (24), oxidative stress, insulin resistance (7), inflammation (8), dyslipidemia (25), elevated plasma homocysteine (26), the accumulation of advanced glycation end products (27), anemia (28), left ventricular hypertrophy (29), arterial calcification (30), and endothelial dysfunction (31).”
BackgroundHarrell, F., Jr. (1996) · doi:10.1002/(sici)1097-0258(19960229)15:4<361::aid-sim168>3.0.co;2-4
Cited by
Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60591-7 · Cited by 2,931
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
Genetics of diabetes mellitus and diabetes complications
Cole, J. B., & Florez, J. C. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0278-5 · Cited by 1,797
DiMeglio, L. A., Evans-Molina, C., & Oram, R. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31320-5 · Cited by 1,561
Kidney disease and increased mortality risk in type 2 diabetes
Afkarian, M., Sachs, M. C., Kestenbaum, B., Hirsch, I. B., Tuttle, K. R., Himmelfarb, J., & de Boer, I. H. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012070718 · Cited by 1,298
Metadata
- Authors
- Groop, P.-H., Thomas, M. C., Moran, J. L., Wadèn, J., Thorn, L. M., Mäkinen, V.-P., Rosengård-Bärlund, M., Saraheimo, M., Hietala, K., Heikkilä, O., & Forsblom, C.
- Affiliations
- Helsinki University Hospital (FI)
- Baker Heart and Diabetes Institute (AU)
- Department of Intensive Care Medicine, The Queen Elizabeth Hospital, Woodville, South Australia, Australia;
- Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland;
- Corresponding author
- Groop, Per-Henrik
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2009-04-28
- Volume
- 58
- Issue
- 7
- Pages
- 1651-1658
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2699848
- OpenAlex
- W2101457616
- Semantic Scholar
- 8c94474962d440b785728afdfb3a4ed830eedf9d
- Cited by
- 638
- References
- 49
- Citations by year
- 2026: 14 · 2025: 29 · 2024: 30 · 2023: 38 · 2022: 59 · 2021: 43 · 2020: 40 · 2019: 48 · 2018: 55 · 2017: 43 · 2016: 40 · 2015: 41 · 2014: 54 · 2013: 40 · 2012: 23
- FWCI
- 14.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by-nc-nd)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- Funders
- Wilhelm och Else Stockmanns Stiftelse
- European Commission
- Signe ja Ane Gyllenbergin Säätiö
- Waldemar von Frenckells Stiftelse
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 1 diabetes, chronic kidney disease, all-cause mortality, diabetic nephropathy, albuminuria, microalbuminuria, macroalbuminuria, end-stage renal disease, glomerular filtration rate, hyperfiltration, standardized mortality ratio
- MeSH terms
- Adolescent, Adult, Cause of Death, Diabetes Mellitus, Type 1, Diabetic Nephropathies, Female, Finland, Follow-Up Studies, Glomerular Filtration Rate, Humans, Insulin, Male, Middle Aged, Severity of Illness Index, Cohort Studies, Age of Onset, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.